Levi & Korsinsky, LLP announces that an FLGT class action lawsuit has been filed on behalf of investors who purchased Fulgent Genetics, Inc. (FLGT) securities between March 22, 2019, and August 4, 2022. For more on the FLGT Lawsuit please contact us today.

According to the Fulgent lawsuit, throughout the Class Period defendants made false and misleading statements and failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE FLGT CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Fulgent you have until November 21, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com